Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Clinical development of metabolic inhibitors for oncology

Journal of Clinical Investigation(2022)10.1172/jci148550Source: DataRank Database

Clinical development of metabolic inhibitors for oncology is a research paper published in Journal of Clinical Investigation (2022). On theSindex it has a DataRank of 0. It has been cited 137 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access137 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 12.19)OA: goldTopics (16)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC, OpenAlex)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Sadakatali S. Gori ORCID,Takashi Tsukamoto ORCID,Rana Rais ORCID,Barbara S. Slusher ORCID,Kathryn M. Lemberg ORCID

Live enrichment

PubMed:34981784 PMC:PMC8718137 OpenAlex:https://openalex.org/W4205900125

NCI NIH HHS

Grant: R01 CA193895

NCI NIH HHS

Grant: R01 CA229451

NCI NIH HHS

Grant: R01 CA226765

NINDS NIH HHS

Grant: R01 NS103927

FWCI

12.19

Citation Percentile

1.0%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttp://www.jci.org/articles/view/148550/files/pdf

publisherhttp://www.jci.org/articles/view/148550/files/pdf

publisherhttps://www.jci.org/articles/view/148550/files/pdf

journalhttps://doi.org/10.1172/jci148550

repositoryhttps://pubmed.ncbi.nlm.nih.gov/34981784

Fields of Study

Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and CancerCancer, Lipids, and Metabolism

MeSH Terms

AnimalsAntineoplastic AgentsHumansNeoplasmsDrug Delivery SystemsTumor Microenvironment

Keywords

Tumor microenvironmentImmune systemClinical OncologyCellular metabolismDrug developmentCell metabolismTumor cells

Additional file 1 of Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer

10.6084/m9.figshare.26360879.v1figshare

Additional file 1 of Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer

10.6084/m9.figshare.26360879figshare

Additional file 1 of FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma

10.6084/m9.figshare.26562196.v1figshare

Additional file 1 of FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma

10.6084/m9.figshare.26562196figshare

Additional file 7 of Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer

10.6084/m9.figshare.26753020.v1figshare

Additional file 6 of Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer

10.6084/m9.figshare.26753014.v1figshare

Additional file 7 of Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer

10.6084/m9.figshare.26753020figshare

Additional file 2 of Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer

10.6084/m9.figshare.26361085.v1figshare

Additional file 4 of Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer

10.6084/m9.figshare.26753008figshare

Additional file 4 of Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer

10.6084/m9.figshare.26753008.v1figshare

Additional file 5 of Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer

10.6084/m9.figshare.26753011figshare

Additional file 2 of Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer

10.6084/m9.figshare.26361085figshare

Additional file 3 of Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer

10.6084/m9.figshare.26753005.v1figshare

Additional file 3 of Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer

10.6084/m9.figshare.26753005figshare

Additional file 5 of Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer

10.6084/m9.figshare.26753011.v1figshare

Additional file 6 of Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer

10.6084/m9.figshare.26753014figshare

Additional file 2 of FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma

10.6084/m9.figshare.26562199.v1figshare

Additional file 5 of FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma

10.6084/m9.figshare.26562208figshare

Additional file 3 of FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma

10.6084/m9.figshare.26562202.v1figshare

Additional file 2 of FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma

10.6084/m9.figshare.26562199figshare

Clinical development of metabolic inhibitors for oncology

FAIR Checklist

Authors (5)

Funding (4 grants)

Impact

Open Access

Topics

Linked Datasets (25)

Annotations (Europe PMC)